Serial 89Zr-bevacizumab PET in Patients with Neuroendocrine Tumors before and on Everolimus Treatment

#912

Introduction: Everolimus increases PFS in patients with advanced NETs. Currently, no biomarkers are available for early selection of patients who will benefit from everolimus. Everolimus can reduce VEGF-A production by tumor cells.

Aim(s): Therefore, we aimed to investigate the effect of everolimus on tumor uptake of radioactive labelled VEGF-A antibody bevacizumab with PET in NET patients.

Materials and methods: Fourteen patients with advanced progressive well-differentiated NET underwent 89Zr-bevacizumab PET scans before, and at two and 12 weeks on everolimus treatment. 89Zr-bevacizumab uptake was quantified by SUVmax. Tumor response and % change in sum of target lesion diameters was determined according to RECIST1.1 on CT 3-monthly.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Brouwers A, Van Asselt S, Oosting S, De Jong J, Lub-de Hooge M,

Keywords: neuroendocrine tumors, 89Zr-bevacizumab PET, VEGF-A, everolimus, biomarker,